Abstract
Cyclamen europaeum tubers extract (CTE) with concentration commonly used for human rhinosinusitis treatment was tested as mucosal adjuvant in experimental intranasal immunization of guinea pigs with concentrated commercially available influenza trivalent vaccine and subsequent infection with influenza strain A/California/04/2009 H1N1pdm. Dual intranasal immunization with vaccine compound consisting of 7.5 µg of each hemagglutinin and 500 µg of CTE in 50 µl induced reciprocal GMT on day 21 after immunization 40 (5-640) against H1N1pdm; 43.20 (5-1280) against H3N2; 10.80 (5-80) against influenza B. Animals with HI titers 1/80 against cell-derived antigen were completely protected against challenge with A/California/04/2009 H1N1pdm09.
This is a preview of subscription content, log in via an institution to check access.
References
Quan FS, Compans RW, Kang SM (2012) Oral vaccination with inactivated influenza vaccine induces cross-protective immunity. Vaccine 30(2):180–188
Tamura S-I, Asanuma H, Ito Y, Hirabayashi Y, Suzuki Y, Nagamine T et al (1992) Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol 22:477–481. https://doi.org/10.1002/eji.1830220228
Pfaar O, Mullol J, Anders C, Hörmann K, Klimek L (2012) Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute rhinosinusitis: a randomized double-blind, placebo-controlled trial. Rhinology 50(1):37–44
Gudymo AS, Maltsev SV, Evseenko VA, Danilchenko NV, Marchenko VY, Durymanov AG et al (2017) Cyclamen europaeum (Cyclamen purpurascens) extract as adjuvant for nasal immunization of mice with influenza antigens. BIOprep Prev Diagn Treat 17(4):233–239
World Health Organization (2004) WHO manual on animal influenza diagnosis and surveillance. http://apps.who.int/iris/bitstream/10665/68026/1/WHO_CDS_CSR_NCS_2002.5.pdf. Accessed 10 Apr 2017
Acknowledgements
The authors thank Dr. Jacqueline Katz (CDC, GA, US) for providing virus strain, antigens and sera through IRR.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This research study was funded by Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor).
Conflict of interest
Vasily A. Evseenko declares that he has no conflict of interest. Natalia P. Kolosova declares that she has no conflict of interest. Anderi S. Gudimo declares that he has no conflict of interest. Semion V. Maltsev declares that he has no conflict of interest. Julia A. Bulanovich declares that she has no conflict of interest. Nataliya I. Goncharova declares that she has no conflict of interest. Natalia V. Danilchenko declares that she has no conflict of interest. Vasiliy Y. Marchenko declares that he has no conflict of interest. Ivan M. Susloparov declares that he has no conflict of interest. Alexander B. Ryzhikov declares that he has no conflict of interest.
Ethical approval
All applicable international, national and institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.
Additional information
Handling Editor: Hans Dieter Klenk.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Evseenko, V.A., Kolosova, N.P., Gudymo, A.S. et al. Intranasal immunization of guinea pig with trivalent influenza antigen adjuvanted by Cyclamen europaeum tubers extract. Arch Virol 164, 243–247 (2019). https://doi.org/10.1007/s00705-018-4023-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00705-018-4023-3